Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$41.11 USD
+0.28 (0.69%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $41.11 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AMPH 41.11 +0.28(0.69%)
Will AMPH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AMPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMPH
New Strong Sell Stocks for April 26th
Amphastar Pharmaceuticals (AMPH) Stock Moves -1%: What You Should Know
AMPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Amphastar (AMPH) a Buy as Wall Street Analysts Look Optimistic?
Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note
Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know
Other News for AMPH
Amphastar Pharmaceuticals Poised for Growth: Strong Generic Pipeline and Strategic Marketing Drive Buy Rating
Commit To Buy Amphastar Pharmaceuticals At $22.50, Earn 18.5% Annualized Using Options
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Ascendis Pharma (ASND) and AMN Healthcare Services (AMN)
Needham Sticks to Its Hold Rating for Amphastar Pharmaceuticals (AMPH)
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies